Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients

« Previous Next »Leukemia Research
Volume 30, Issue 6 , Pages 701-705, June 2006

Jeyanthi Ramanarayanan
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Lauren M. Dunford
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Maria R. Baer
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Sheila N.J. Sait
- Clinical Cytogenetics Laboratory, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
William Lawrence
- Century Medical Group, Buffalo, NY, USA
Philip L. McCarthy
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
- Corresponding author. Present address: Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Tel.: +1 716 845 1051; fax: +1 716 845 3272.